Brexafemme

Boxed Warning — Brexafemme: Brexafemme can cause fetal harm based on animal studies. Pregnancy should be excluded before starting treatment, and effective contraception used during treatment. When used monthly for recurrent VVC prevention, pregnancy status should be reassessed before each dose.

Brexafemme Warnings and Precautions

• Embryo-fetal toxicity: See boxed warning above — Brexafemme is contraindicated in pregnancy.
• Hypersensitivity: Brexafemme is contraindicated in patients with known hypersensitivity to ibrexafungerp.
• Not for systemic fungal infections: Brexafemme is intended for vulvovaginal candidiasis only, not invasive or systemic fungal infections.

How to Access Brexafemme in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation & Availability

What documents are required to import Brexafemme to India?

Brexafemme (ibrexafungerp) tablets may be imported in the patient's name only, by patients or government hospitals, in line with India's import regulations for unapproved medicines. The following documentation is required:

• A valid prescription from a qualified gynecologist or physician
• The patient's diagnostic reports confirming vulvovaginal candidiasis
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription from the doctor and, if applicable, an import permit.

Is Brexafemme available in India?

Brexafemme (ibrexafungerp tablets) is a prescription medicine that legally requires a doctor's prescription to be dispensed. As of current publicly available information, Brexafemme is not commercially marketed in India.

However, patients in India can legally access Brexafemme through the Named Patient Program (NPP) — an import provision that allows patients to receive medicines approved in other countries but not yet marketed in India, under a doctor's prescription and proper regulatory documentation.

Brexafemme received US FDA approval in 2021 for vulvovaginal candidiasis, with a second indication for recurrent VVC prevention approved in 2022, ensuring full transparency throughout the process.

Brexafemme can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others.

Sourcing & Delivery of Brexafemme

Brexafemme is sourced directly from authorized channels in the country of origin and shipped to India under GDP-compliant logistics to preserve product integrity from dispatch to delivery.

• Storage maintained at 15°C to 30°C throughout transit
• Real-time shipment tracking and delivery updates
• Delivery coordinated directly with the patient, family, or treating hospital

Availability of Brexafemme Across Major Cities in India

Named Patient Program supports access to Brexafemme for patients with vulvovaginal candidiasis across major cities in India, coordinating documentation, sourcing, and delivery with treating physicians.

Mumbai

Patients in Mumbai can access Brexafemme through NPP with support from treating gynecologists.

Delhi

In Delhi, NPP coordinates with hospitals and specialty gynecology clinics to facilitate timely access to Brexafemme.

Bangalore

Bangalore's gynecology centers work with NPP to support patients requiring Brexafemme.

Chennai

Patients in Chennai can access Brexafemme through NPP, with coordination between treating doctors and the program's regulatory and logistics team.

Hyderabad

Hyderabad's gynecology centers support diagnosis and access coordination for Brexafemme through NPP.

Kolkata

NPP facilitates access to Brexafemme for patients in Kolkata under the guidance of treating physicians.

Pune

Patients in Pune can access Brexafemme through NPP with prescription-based coordination and delivery support.

Ahmedabad

NPP supports access to Brexafemme for patients in Ahmedabad, working directly with treating specialists.

Kochi

Patients in Kochi and across Kerala can access Brexafemme through NPP's regulated import pathway.

Chandigarh

NPP coordinates access to Brexafemme for patients in Chandigarh and the surrounding region.

Jaipur

Patients in Jaipur can access Brexafemme through NPP with support from treating physicians.

Lucknow

NPP facilitates access to Brexafemme for patients in Lucknow and across Uttar Pradesh.

Bhubaneswar

Patients in Bhubaneswar can access Brexafemme through NPP's coordinated import and delivery process.

Guwahati

NPP supports access to Brexafemme for patients in Guwahati and across the Northeast region.

NPP also supports access for patients in other Indian cities not listed above — contact the team to check availability and timelines for your location.